

OPHTHALMOLOGY
PAPER-IV

Please read carefully the important instructions mentioned on Page '1'

- Answers to questions of Part A and part B are to be strictly attempted in separate answer sheets and the main + supplementary answer sheets used for each part must be tagged separately.
- Answers to question(s) of Part A attempted in answer sheets of Part B or vice versa shall not be evaluated.

PART B

- | | | |
|-----|--|-------|
| 6. | a) Define dry eyes as per DEWS 2 report. | 3+2+5 |
| | b) Role of anti-inflammatory agents in management of dry eyes. | |
| | c) Diagnosis and management of Meibomian gland disease. | |
| 7. | a) Visual prosthesis. | 5+5 |
| | b) Keratoprosthesis. | |
| 8. | a) Ocular surface reconstruction. | 4+6 |
| | b) SLET - Indications, intraoperative & postoperative complications and their management. | |
| 9. | a) Bevacizumab – Mechanism of action, indications and differences with other drugs of same group. | 6+4 |
| | b) Discuss in brief CATT 1 and CATT 2 trials. | |
| 10. | Enumerate and describe role of biomarkers which may be beneficial in diagnosis, pathogenesis, treatment strategies and prevention of various ocular morbidities. | 10 |
